Published in Schizophr Res on July 18, 2008
Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits. Schizophr Res (2010) 1.02
Sensation/novelty seeking in psychotic disorders: A review of the literature. World J Psychiatry (2015) 0.78
Parkinsonian motor impairment predicts personality domains related to genetic risk and treatment outcomes in schizophrenia. NPJ Schizophr (2017) 0.75
Psychometric properties of the Greek TCI-R and its clinical correlates: schizotypy and the self-regulation of affective and cognitive functioning. PeerJ (2016) 0.75
Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med (2006) 4.16
Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry (2007) 3.22
Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry (2007) 2.13
The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res (2005) 1.55
Preserved awareness of their cognitive deficits in patients with schizophrenia: convergent validity of the SSTICS. Schizophr Res (2008) 1.48
Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis. Drug Saf (2012) 1.42
Sleep in untreated patients with schizophrenia: a meta-analysis. Schizophr Bull (2004) 1.31
Should we treat auditory hallucinations with repetitive transcranial magnetic stimulation? A metaanalysis. Can J Psychiatry (2008) 1.09
Assessment of executive dysfunction during activities of daily living in schizophrenia. Schizophr Res (2004) 1.07
A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry (2011) 1.06
Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls? Schizophr Res (2008) 1.06
Self-assessed cognitive dysfunction and objective performance in outpatients with schizophrenia participating in a rehabilitation program. Schizophr Res (2004) 1.04
Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophr Res (2005) 1.04
Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. Eur Psychiatry (2007) 1.01
Cerebral activity associated with auditory verbal hallucinations: a functional magnetic resonance imaging case study. J Psychiatry Neurosci (2002) 1.01
CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain Cogn (2005) 1.00
Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. Schizophr Res Treatment (2012) 1.00
Predictors of quality of life in schizophrenia. Community Ment Health J (2005) 1.00
Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci (2007) 0.99
Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr Res (2007) 0.98
Sleep architecture and its clinical correlates in first episode and neuroleptic-naive patients with schizophrenia. Schizophr Res (2003) 0.98
Effects of cognitive remediation therapies on psychotic symptoms and cognitive complaints in patients with schizophrenia and related disorders: a randomized study. Schizophr Res (2009) 0.97
Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders. Eur Arch Psychiatry Clin Neurosci (2014) 0.95
The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency. Can J Psychiatry (2004) 0.94
Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf (2008) 0.93
Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: an fMRI study. Psychiatry Res (2005) 0.92
Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology (Berl) (2003) 0.92
Pain perception in schizophrenia: no changes in diffuse noxious inhibitory controls (DNIC) but a lack of pain sensitization. J Psychiatr Res (2008) 0.90
ERP investigation of study-test background mismatch during face recognition in schizophrenia. Schizophr Res (2011) 0.89
Sexual dimorphism in schizophrenia: is there a need for gender-based protocols? Expert Rev Neurother (2011) 0.89
Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Curr Med Res Opin (2007) 0.89
Pain perception in schizophrenia: evidence of a specific pain response profile. Pain Med (2012) 0.88
Treating delusional disorder: a comparison of cognitive-behavioural therapy and attention placebo control. Can J Psychiatry (2007) 0.88
Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol (2011) 0.88
Neural correlates of emotional recognition memory in schizophrenia: effects of valence and arousal. Psychiatry Res (2011) 0.87
Could the use of energy drinks induce manic or depressive relapse among abstinent substance use disorder patients with comorbid bipolar spectrum disorder? Bipolar Disord (2011) 0.87
Differential hemodynamic brain activity in schizophrenia patients with blunted affect during quetiapine treatment. J Clin Psychopharmacol (2005) 0.87
Disturbed sexual dimorphism of brain activation during mental rotation in schizophrenia. Schizophr Res (2010) 0.87
Agenesis of corpus callosum and emotional information processing in schizophrenia. Front Psychiatry (2012) 0.87
Sleep habits in middle-aged, non-hospitalized men and women with schizophrenia: a comparison with healthy controls. Psychiatry Res (2010) 0.87
An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis. Clin Schizophr Relat Psychoses (2013) 0.86
A study of theory of mind in paranoid schizophrenia: a theory or many theories? Front Psychol (2012) 0.85
Sensation-seeking, social anhedonia, and impulsivity in substance use disorder patients with and without schizophrenia and in non-abusing schizophrenia patients. Psychiatry Res (2012) 0.85
Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophr Res (2009) 0.85
Daily activities, cognition and community functioning in persons with schizophrenia. Schizophr Res (2008) 0.85
Attention and non-REM sleep in neuroleptic-naive persons with schizophrenia and control participants. Psychiatry Res (2006) 0.85
Memory and executive functions in adults with Gilles de la Tourette syndrome and chronic tic disorder. Cogn Neuropsychiatry (2007) 0.84
Do patients with schizophrenia attribute mental states in a referential communication task? Cogn Neuropsychiatry (2009) 0.84
Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J Psychopharmacol (2008) 0.84
The incidence and nature of cerebellar findings in schizophrenia: a quantitative review of fMRI literature. Schizophr Bull (2012) 0.84
Use of the process dissociation procedure to study the contextual effects on face recognition in schizophrenia: familiarity, associative recollection and discriminative recollection. Psychiatry Res (2006) 0.84
The crucial role of sustained attention in community functioning in outpatients with schizophrenia. Psychiatry Res (2004) 0.84
Relationship between psychotic and obsessive compulsive symptoms in schizophrenia. Schizophr Res (2009) 0.84
Mild procedural learning disturbances in neuroleptic-naive patients with schizophrenia. J Neuropsychiatry Clin Neurosci (2003) 0.83
Processing of social emotion in patients with schizophrenia and substance use disorder: an fMRI study. Soc Neurosci (2007) 0.83
Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J Clin Psychopharmacol (2010) 0.82
Genealogy of instruments for prodrome evaluation of psychosis. Front Psychiatry (2013) 0.82
Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders. Schizophr Res (2005) 0.82
Procedural learning in schizophrenia can reflect the pharmacologic properties of the antipsychotic treatments. Cogn Behav Neurol (2004) 0.82
Sex differences in the cerebral function associated with processing of aversive stimuli by schizophrenia patients. Aust N Z J Psychiatry (2007) 0.82
Electrophysiological manifestations of stimulus evaluation, response inhibition and motor processing in Tourette syndrome patients. Psychiatry Res (2009) 0.82
[The role of social support, family burden and satisfaction with services in psychological distress and quality of life of families of individuals with schizophrenia]. Sante Ment Que (2005) 0.82
Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Mov Disord (2010) 0.81
Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. Expert Opin Drug Saf (2012) 0.81
Increased striatal gray matter densities in patients with schizophrenia and substance use disorder: a voxel-based morphometry study. Psychiatry Res (2007) 0.81
Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia. Am J Drug Alcohol Abuse (2008) 0.81
The cognitive and anatomo-functional basis of reality distortion in schizophrenia: a view from memory event-related potentials. Psychiatry Res (2003) 0.81
Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin (2006) 0.81
Language functions in right-hemisphere damage and schizophrenia: apparently similar pragmatic deficits may hide profound differences. Brain (2007) 0.81
Sexual dimorphism of spatial working memory profiles in schizophrenia. Cogn Neuropsychiatry (2010) 0.81
Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin (2007) 0.80
Genes and memory: the neuroanatomical correlates of emotional memory in monozygotic twin discordant for schizophrenia. Brain Cogn (2004) 0.80
Brain-behavior relations during motor processing in chronic tic and habit disorder. Cogn Behav Neurol (2005) 0.80
Are there common mechanisms in sensation seeking and reality distortion in schizophrenia? A study using memory event-related potentials. Psychiatry Res (2005) 0.80
Meta-analysis of depressive symptoms in dual-diagnosis schizophrenia. Aust N Z J Psychiatry (2007) 0.80
Working memory and depressive symptoms in patients with schizophrenia and substance use disorders. Cogn Neuropsychiatry (2008) 0.79
Cognitive behavioral management of Tourette's syndrome and chronic tic disorder in medicated and unmedicated samples. Behav Res Ther (2009) 0.79
Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int Clin Psychopharmacol (2003) 0.79
The paradox of quetiapine in obsessive-compulsive disorder. CNS Spectr (2005) 0.79
Use of the Perceive, Recall, Plan and Perform System of Task Analysis for persons with schizophrenia: a preliminary study. Aust Occup Ther J (2009) 0.79
The relationships between symptom dimensions and dysphoria in schizophrenia. Schizophr Res (2005) 0.79
Clinical evolution of substance use disorder patients during treatment with quetiapine: a 12-week, open-label, naturalistic trial. Expert Opin Pharmacother (2010) 0.79
Mismatched expressions decrease face recognition and corresponding ERP old/new effects in schizophrenia. Neuropsychology (2012) 0.79
Neural correlates of the affect regulation model in schizophrenia patients with substance use history: a functional magnetic resonance imaging study. J Clin Psychiatry (2006) 0.79
ERP study of pre-attentive auditory processing in treatment-refractory schizophrenia. Brain Cogn (2004) 0.79
Oral cholinesterase inhibitor add-on therapy for cognitive enhancement in schizophrenia: a quantitative systematic review, Part I. Clin Neuropharmacol (2007) 0.79
Ecological assessments of activities of daily living and personal experiences with Mobus, an assistive technology for cognition: a pilot study in schizophrenia. Assist Technol (2012) 0.79
Decrease in basal ganglia grey matter density associated with atypical antipsychotic treatment in schizophrenia patients. Schizophr Res (2008) 0.79
Relationship between insight into cognition, extrapyramidal symptoms and mental illness in schizophrenia. Aust N Z J Psychiatry (2011) 0.78